These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20599369)

  • 1. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.
    Molimard M; Buhl R; Niven R; Le Gros V; Thielen A; Thirlwell J; Maykut R; Peachey G
    Respir Med; 2010 Sep; 104(9):1381-5. PubMed ID: 20599369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
    Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients.
    Domingo C; Moreno A; José Amengual M; Montón C; Suárez D; Pomares X
    Curr Med Res Opin; 2011 Jan; 27(1):45-53. PubMed ID: 21083517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.
    Liebhaber M; Dyer Z
    J Asthma; 2007 Apr; 44(3):195-6. PubMed ID: 17454337
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
    Rottem M
    J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of omalizumab in a severe asthma clinic.
    Gibson PG; Taramarcaz P; McDonald VM
    Respirology; 2007 Nov; 12 Suppl 3():S35-44; discussion S45-7. PubMed ID: 17956518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic effects of suboptimally controlled asthma.
    Bootman JL; Crown WH; Luskin AT
    Manag Care Interface; 2004 Jan; 17(1):31-6. PubMed ID: 15035598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.
    Korn S; Schumann C; Kropf C; Stoiber K; Thielen A; Taube C; Buhl R
    Ann Allergy Asthma Immunol; 2010 Oct; 105(4):313-9. PubMed ID: 20934632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma.
    Karpel J; Massanari M; Geba GP; Kianifard F; Inhaber N; Zeldin RK
    Ann Allergy Asthma Immunol; 2010 Dec; 105(6):465-70. PubMed ID: 21130385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
    Pace E; Ferraro M; Bruno A; Chiappara G; Bousquet J; Gjomarkaj M
    J Asthma; 2011 May; 48(4):387-92. PubMed ID: 21391878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of omalizumab therapy in a patient with severe persistent allergic asthma and hepatitis C.
    Antonicelli L; Stagnozzi G; Giuliodoro S; Abbruzzetti A; Massaccesi C
    Ann Allergy Asthma Immunol; 2009 Sep; 103(3):269-70. PubMed ID: 19788028
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma.
    Ververeli K; Chipps B
    Ann Allergy Asthma Immunol; 2004 May; 92(5):512-22. PubMed ID: 15191019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab (Xolair) in patients with steroid-resistant asthma: lessons to be learnt.
    Thompson PJ; Misso NL; Woods J
    Respirology; 2007 Nov; 12 Suppl 3():S29-34; discussion S45-7. PubMed ID: 17956517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When oral corticosteroids are essential for persistent severe asthma.
    Greenberger PA
    J Allergy Clin Immunol; 2010 Feb; 125(2):511-3. PubMed ID: 20159270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.